Wir möchten auf unserer Internetseite Dienste von Drittanbietern nutzen, die uns helfen, unsere Werbeangebote zu verbessern (Marketing), die Nutzungsweise unserer Internetseite auszuwerten (Performance) und die Internetseite an Ihre Vorlieben anzupassen (Funktional). Für den Einsatz dieser Dienste benötigen wir Ihre Einwilligung, welche jederzeit widerrufen werden kann. Informationen zu den Diensten und eine Widerspruchsmöglichkeit finden Sie unter „Benutzerdefiniert“. Weitergehende Informationen finden Sie in unserer Datenschutzerklärung.
Darktrace Antigena is an active, self-defence product that extends Darktrace’s core power of detection, acting as digital antibodies within the Enterprise Immune System.
As the human immune system produces antibodies to identify and neutralize potential threats, Darktrace’s Enterprise Immune System technology produces an Antigena response to automatically defend against potential threats in real time.
As such, Darktrace Antigena is a unique product, complementing Darktrace’s core detection capability. It allows critical, mitigating action to be taken, without human intervention – and faster than any security team can respond. Depending on the severity of the anomalous activity detected by Darktrace, these responses could involve:
Stopping or slowing down activity related to a specific threat
Quarantining people, systems or devices
Marking specific pieces of content for further investigation or tracking
Action taken by Darktrace is highly targeted, thanks to the unique ability of the Enterprise Immune System to detect genuine threats, without false positives. Darktrace Antigena simply enforces the normal ‘pattern of life’ of a device or user, without causing unnecessary and disruptive side-effects on business operations.
Darktrace Antigena is uniquely capable of:
Directly inoculating against a full range of threats
Preventing, slowing or disrupting activity in real time
Stopping threats before they spread
Antigena is available in three modules:
Antigena Internet — regulates user and machine access to the internet and beyond
Antigena Communication — regulates email, chat and other messaging protocols
Antigena Network — regulates machine and network connectivity, and user access permissions
Darktrace Antigena modules are deployed as physical appliances, complementing the core Enterprise Immune System appliance. They can also interface with Software Defined Networks (SDN) and Active Directory, and are fully configurable.
Leider gibt es für diesen Aussteller kein deutsches Firmenprofil.
Darktrace was founded in Cambridge, UK, in 2013 by mathematicians and machine learning specialists from the University of Cambridge, together with world-leading intelligence experts from MI5 and GCHQ, to bring transformative technology to the challenge of cyber security.
With this unique combination of expertise in mathematics, software and intelligence, Darktrace has delivered the world’s first operational Enterprise Immune System. Our leading-edge solution gives organizations the ability to detect emerging cyber-threats, allowing them the opportunity to proactively defend against in-progress cyber-attacks.
Our executive team has extensive experience in government intelligence and cyber operations and the protection of critical national infrastructure. This team is supported by a specialist cyber analyst team, with unparalleled experience of some of the most sophisticated threats in today’s complex security environment.
Darktrace has experienced rapid growth since its foundation, growing revenues by over 100% and doubling the number of employees from 2014–15. It was named ‘Best Security Company of the Year 2016’ at the Info Security Global Excellence Awards and a Gartner ‘Cool Vendor’ 2015.
We have raised over $40 million in funding from investors including Invoke Capital, Talis Capital, Hoxton Ventures and Summit Partners.
Darktrace is headquartered in Cambridge, UK and San Francisco, with global offices in London, Paris, Milan, Singapore, Tokyo, New York, Chicago, Washington D.C., Boston, Los Angeles, Dallas, Toronto, Auckland and Sydney.